

Session #1

P. Delanaye
CHU Liège



M. Taghavi
CHU Brugman

Maxime Taghavi is a nephrologist at CHU Brugmann since 2020. His clinical activity focuses on peritoneal dialysis and clinical nephrology. He is pursuing a PhD focusing on the role of the vascular endothelium in the pathogenesis of arteriovenous fistula maturation failure in hemodialysis patients with persistent antiphospholipid antibody (aPL) positivity. His broader research interests include lupus nephritis, aPL-associated nephropathy, catastrophic antiphospholipid syndrome, and secondary thrombotic microangiopathies.



S. Van Laecke
UZ Gent

Prof. dr. Van Laecke is nephrologist at Ghent University Hospital. His dissertation was on the role of magnesium in glucose metabolism and vascular disease. His interests are kidney transplantation, glomerular disease, and translational medicine including immunosenescence.

P. Romagnani
University of Florence
Italy

T. Van Meerhaeghe
Erasme

Dr Tess VAN MEERHAEGHE currently serves as a medical doctor in the Department of Nephrology at Hôpital Erasme, Université Libre de Bruxelles. She earned her medical degree from the Vrije Universiteit Brussels and her expertise encompasses systemic disease and transplant immunology. Her research focuses on immune checkpoint inhibitors in renal transplant recipients.



R. Vanholder

Dr. Vanholder published more than 900 papers, including reviews and book chapters, on adequacy of dialysis, uremic toxicity and various topics related to clinical nephrology, especially cardio-vascular and infectious complications. He serves as a member of the editorial review board of several journals and is subject editor of Nephrology Dialysis and Transplantation and Toxins. Up till autumn 2010, he has been chairman of the European Uremic Toxin Work Group (EUTox) and member of the Executive Board and treasurer of Kidney Disease Improving Global Outcomes (KDIGO). Up till summer 2011 he was chairman of the European Renal Best Practice (ERBP). Up till autumn 2014, he chaired the Renal Disaster Relief Task Force (RDRTF) of the International Society of Nephrology (ISN) and participated in several international relief operations. Dr. Vanholder was founding president of the Belgian Society of Nephrology (BVN-SBN), is past president of the European Society of Artificial Organs (ESAO) and past president of ERA-EDTA. He is now retired (Prof Em at Ghent University) and also past president of the European Kidney Health Alliance and of the European Chronic Disease Alliance.

Session #2



J. Floege
RWTH Aachen
University,
Aachen Germany

Professor Jürgen Floege trained at the Hannover Medical School, Germany, the Albert Einstein College of Medicine, New York and the University of Washington, Seattle, USA. He was head of the Division of Nephrology and Immunology at the University of Aachen, Germany from 1999 to July 31, 2023.

Thereafter he was awarded the position of a senior professor at the RWTH Aachen University Medical School.

Professor Floege is a former executive council member of the International Society of Nephrology (ISN), the European Renal Association (ERA-EDTA), and KDIGO. He is a Distinguished Fellow of the ERA-EDTA and recipient of the 2018 ERA-EDTA Award for Outstanding Clinical Contributions to Nephrology. He also is past-president of the German Society of Nephrology and recipient of the 2020 Volhard medal of that society in honor of his life-time achievements.

Together with Professors Richard Johnson and Marcello Tonelli he edits the best-selling textbook "Comprehensive Clinical Nephrology". Finally, Professor Floege is associate editor of Kidney International since Jan 2018 and editor-in-chief of Clinical Kidney Journal since Sept 2023. Until 2017 he served as associate editor of Nephrology, Dialysis Transplantation.

Research interests encompass both basic research, i.e. studies underlying progression of renal disease in particular renal fibrosis, as well as clinical research in immune-mediated renal disease, in particular IgA-nephropathy, as well as bone and mineral disorders (CKD-MBD) and cardiovascular disease in uremic patients. He coordinates the KDIGO world-wide guidelines on the management of glomerular diseases.

His scientific work encompasses more than 800 original papers, reviews and editorials.



H-J Anders
University of Munich
(LMU)

Hans-Joachim Anders received his clinical training at the University of Munich and became a board-certified internist, nephrologist, rheumatologist, and immunologist. He directs the Division of Nephrology at the Inner City Campus of the University of Munich. As a professor of nephrology at the University of Munich, he teaches all aspects of clinical nephrology and coordinates the Medical Faculty's "Molecular Medicine" research program for medical students. His research lab focusses on translational aspects of kidney necroinflammation and preclinical drug testing. He has published more than 450 original articles, reviews, and book chapters and received several national and international awards, e.g., the award for outstanding contributions in basic science in nephrology of the European Renal Association in 2018. He serves the ERA and the ISN in various boards devoted to clinical nephrology and translational research and is Editor-in-Chief of Nephrol Dial Transplantation.



V. Gillion
Cliniques Universitaires
Saint-Luc

Dr. Gillion is a nephrologist working at the Cliniques Universitaires Saint-Luc since 2016. She treats patients with genetic kidney diseases (Alport syndrome, Fabry disease, Tuberous sclerosis) as well as patients with kidney stones and tubulopathies. She is currently pursuing a PhD in partnership with KU Leuven and Prof. Claes on dominant Alport syndrome and women with X-linked Alport syndrome. Dr. Gillion also teaches nephrology to 4th-year medical students at UCLouvain.

Clinical-pathological conference

A. Van Craenenbroeck
UZ Leuven

A. Dendooven
UZ Gent

C. Van Aerde
UZ Leuven

D. Trouet
UZ Antwerpen

A. Massart
UZ Antwerpen

S. Deffrennes
Hasselt

Session #3

Michel Jadoul
Cliniques universitaires
Saint-Luc



D. Kuypers
UZ Leuven

Professor Dr Kuypers is Chair of the Department of Nephrology and Director of the Renal Transplantation Program at the University Hospitals Leuven. He is professor of Medicine and Head of the Laboratory of Nephrology (Nephrology Research Group), Department of Microbiology, Immunology and transplantation, at the University of Leuven, Belgium. He has an appointment as specialist in Clinical Pharmacology and Pharmaceutical Science. Research activities. Clinical and translational research is focused on (personalized and precision) immunosuppressive therapy, clinical pharmacology of immunosuppressive drugs and renal allograft surveillance using protocol biopsies and (bio)markers of allograft status and chronic allograft dysfunction, including metabolomics signatures of under- and over-immunosuppression. Model-informed precision dosing of immunosuppressive drugs (incl. machine learning, AI) at the point-of-care. Introduction of chimeric antigen receptor (CAR-)T-cell therapy in clinical transplantation also belongs to the research portfolio. He participated in more than 80 clinical trials. Professor Kuypers is editorial member of several scientific journals and has (co-)authored more than 420 peer-reviewed scientific papers and has written several book chapters. His current h-index is 75 (Web of Science) and a total of 772 publications are registered in Lirias KU Leuven. He has given more than 100 Invited lectures at International scientific meetings on renal transplantation.



M. Neyt
Federaal Kenniscentrum
voor de Gezondheidszorg

Mattias Neyt is an economist (2000, Ghent University) and obtained a Ph.D. in 2006 from Ghent University in health economics. Since 2005, he has been working at the Belgian Health Care Knowledge Centre (KCE), an independent federal agency providing advice to policy makers, where he is senior health economist. He has co-authored about 40 'Health Technology Assessment' (HTA) and 'Health Services Research' (HSR) projects and about 70 journal articles. He is author of the Belgian guidelines for economic evaluations, the EUnetHTA guidelines for measuring health-related quality of life and the EUnetHTA guidance document with practical considerations when critically assessing economic evaluations. He is also a member of the European methodological and procedural guidance group. As an independent consultant (ME-TA) he also conducts systematic reviews and HTAs for foreign non-profit organizations and provides professional training in HTA and economic evaluations.

K. M. Wissing
UZ VUB

Prof. Dr. Karl Martin Wissing is Head of the Department of Nephrology at the University Hospital Brussels (UZB) and full professor of Nephrology at the Vrije Universiteit Brussel (VUB), where he is also a member of the Vitality Research Group. He trained in internal medicine and nephrology at the Université Libre de Bruxelles, where he obtained his PhD in Medical Sciences, and later completed an MSc in Epidemiology at the London School of Hygiene and Tropical Medicine (University of London) in 2009.

His clinical and research activities focus on epidemiological studies and clinical trials in renal transplantation and nephrology.

Prof. Wissing has been involved in several national and international professional bodies. He served as Belgian representative on the Eurotransplant Kidney Advisory Committee (ETKAC) from 2004 to 2011 and has been Vice-Chairman of the Eurotransplant Registry Advisory Committee (ERAC) since 2017. He has been a member of the Registry Commission of the Nederlandse Belgische Vereniging voor Nefrologie (NBVN) since 2011 and its treasurer since 2022.

Within the Belgian Transplantation Society (BTS), he has been a Board Member since 2014, a member of the Kidney & Pancreas Advisory Committee (BeKPAC) since 2016, and served as President of BTS from 2020 to 2022. Since 2023, he has chaired the Working Group Nephrology for the Ministry of Public Health on the reform of nephrology training.

K. Claes
UZ Leuven